

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6924286

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	EXECUTIVE ORDER 9424, CONFIRMATORY LICENSE
CONVEYING PARTY DATA	
Name	Execution Date
DANA-FARBER CANCER INST	02/12/2019
RECEIVING PARTY DATA	
Name:	National Institutes of Health (NIH), U.S. Dept. of Health and Human Services (DHHS), U.S. Government
Street Address:	NIH Division of Extramural Inventions and Technology Resources (DEITR)
Internal Address:	6705 Rockledge Drive, Suite 310, MSC 7980
City:	Bethesda
State/Country:	MARYLAND
Postal Code:	20892-7980
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16094102
CORRESPONDENCE DATA	
Fax Number:	(301)480-0272
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Email:	edison@nih.gov
Correspondent Name:	DIRECTOR, DEITR
Address Line 1:	NIH, 6705 ROCKLEDGE DRIVE, SUITE 310
Address Line 2:	MSC 7980
Address Line 4:	BETHESDA, MARYLAND 20892-7980
NAME OF SUBMITTER:	DIRECTOR, DEITR
SIGNATURE:	/DIRECTOR, DEITR/
DATE SIGNED:	09/20/2021
Total Attachments: 1 source=16094102#page1.tif	

License to the United States Government

Sign and submit the executed document to the appropriate funding agency (e.g. upload in iEdison).

Invention Title: SEGREGATION OF CYCLIN-DEPENDENT KINASE 9 (CDK9) BY CONJUGATION OF CDK9 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE

Inventor(s): Nicholas Kwiatkowski, Nathanel Gray, Yanke Liang, Calla Olson, Tinghu Zhang

U.S. Filing/Issue Date: 10/16/2018

Patent or Application Serial No.: 16/094,103

Grant/Contract Number(s): R01 CA179483

Foreign Applications filed/intended in (countries): CHINA, EUR PATENT OFC


The invention identified above is a Subject Invention under **35 U.S.C. 200, et seq.**, and the Standard Patent Rights clause at **37 CFR 401.14, FAR 52.227-11 or FAR 52.227-12** (if applicable) which are included among the terms of the above identified grant or contract award from the United States Government. This document is confirmatory of:

1. The nonexclusive, nontransferable, irrevocable, paid-up license to practice or have practiced for or on behalf of the United States the invention described in any patent application and in any and all divisions, continuations, and continuations in part, and in any and all patents and re-issues granted thereon throughout the world; and
2. All other rights acquired by the Government by reason of the above identified grant/contract award and the laws and regulations that are applicable to the award.

The Government is hereby granted an irrevocable power to inspect and make copies of the above-identified patent application.

Signed this 12th day of February, 2019

By Gary Sclar
(Institutional Business Official)


(Signature)

Title Vice President, Innovation

For DANA-FARBER CANCER INST
(Grantee/Contractor Organization)

At 450 Brookline Avenue BP312 BOSTON, MA 02215
(Business Address)